← All Arcellx, INC filings

Arcellx, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ACLX
Arcellx, INC
10-K/A: Arcellx 10-K/A: Governance and Compensation Update
Arcellx, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding corporate governance, executive compensation, and director information.
NASDAQ
ACLX
Arcellx, INC
10-K: Arcellx to Merge with Gilead, Anito-cel BLA Accepted
Arcellx announced its acquisition by Gilead Sciences for $115.00 per share plus a $5.00 CVR, following FDA acceptance of its BLA for anito-cel in relapsed or refractory multiple myeloma.
NASDAQ
ACLX
Arcellx, INC
10-K: Arcellx Reports Promising Clinical Data and Outlines Strategy in Annual 10-K Filing
Arcellx's 10-K filing highlights positive clinical trial results for anito-cel and outlines strategic initiatives for growth in cell therapy.
NASDAQ
ACLX
Arcellx, INC
10-K: Arcellx Outlines Financials, Strategy and Progress in 10-K Filing
Arcellx's 10-K filing details its financial status, clinical program advancements, and strategic direction in the cell therapy space.